Biogen advances Alzheimer's drug to late-stage trial despite disappointing dataBiogen said signals suggest the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.{}

Biogen said signals suggest the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.https://www.cnbc.com/2026/05/14/biogen-alzheimers-drug-moves-to-late-stage-trial.html